PedAM
Pediatric Disease Annotations & Medicines
| peritonitis | ||||
| Disease ID | 368 |
|---|---|
| Disease | peritonitis |
| Manually Symptom | UMLS | Name(Total Manually Symptoms:56) C2712332 | vomiting C2707258 | infections C2598155 | pain C2364133 | infection C1963154 | renal failure C1704437 | respiratory distress syndrome C1565662 | acute renal insufficiency C1373218 | immunosuppression C1299916 | endotoxicosis C1258215 | ileus C1141926 | abdominal sepsis C1140680 | ovarian cancers C1090821 | sepsis C0948600 | organ failure C0865850 | acute respiratory insufficiency C0796095 | c syndrome C0740265 | acid-base disorders C0728936 | circulatory disorders C0600327 | toxic shock C0542241 | toxemia C0426768 | o sign C0424755 | fever C0375362 | peritoneal adhesions C0342953 | organ dysfunction syndrome C0341163 | perforated gastric ulcer C0268104 | disorders of purine metabolism C0267179 | gastrocolic fistula C0242966 | systemic inflammatory response syndrome C0234244 | somatic pain C0232493 | epigastric pain C0232490 | abdominal crisis C0221163 | motor disorders C0198632 | pneumoperitoneum C0149670 | disorders of carbohydrate metabolism C0087086 | thrombi C0036981 | endotoxic shock C0036690 | septicemia C0035222 | adult respiratory distress syndrome C0030552 | paresis C0030446 | paralytic ileus C0025517 | metabolic disorders C0024115 | pulmonary disorders C0024115 | pulmonary diseases C0023895 | hepatopathy C0022876 | premature labor C0021845 | bowel perforation C0021843 | intestinal obstruction C0021843 | bowel obstruction C0021051 | immunodeficiency C0008149 | chlamydia infection C0006309 | brucellosis C0004610 | bacteremia C0001261 | actinomycosis C0001127 | respiratory acidosis C0001125 | lactic acidosis C0000727 | acute abdomen |
| Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:26) C0036690 | sepsis | 30 C0009450 | infection | 24 C0030193 | pain | 15 C0021311 | infections | 10 C0021843 | bowel obstruction | 7 C0426768 | o sign | 6 C0015967 | fever | 6 C0021843 | intestinal obstruction | 6 C0021845 | bowel perforation | 6 C0796095 | c syndrome | 5 C0032320 | pneumoperitoneum | 5 C1258215 | ileus | 4 C0004610 | bacteremia | 2 C0000727 | acute abdomen | 2 C1141926 | abdominal sepsis | 2 C0600327 | toxic shock | 2 C0030446 | paralytic ileus | 2 C0042963 | vomiting | 2 C0021079 | immunosuppression | 2 C0035078 | renal failure | 1 C0156181 | peritoneal adhesions | 1 C0242966 | systemic inflammatory response syndrome | 1 C0948600 | organ failure | 1 C1299916 | endotoxicosis | 1 C0036690 | septicemia | 1 C0021051 | immunodeficiency | 1 |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:5) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| snpId | pubmedId | geneId | geneSymbol | diseaseId | sourceId | sentence | score | Year | geneSymbol_dbSNP | CHROMOSOME | POS | REF | ALT |
| rs1800450 | 25969530 | 4153 | MBL2 | umls:C0031154 | BeFree | We genotyped and analyzed 4 important MBL2 single nucleotide polymorphisms (SNPs; rs5030737, rs1800450, rs1800451, and rs7096206) in 1839 European community-acquired pneumonia (CAP) and peritonitis sepsis cases, and 477 controls from the United Kingdom. | 0.000814326 | 2015 | MBL2 | 10 | 52771475 | C | T |
| rs1800451 | 25969530 | 4153 | MBL2 | umls:C0031154 | BeFree | We genotyped and analyzed 4 important MBL2 single nucleotide polymorphisms (SNPs; rs5030737, rs1800450, rs1800451, and rs7096206) in 1839 European community-acquired pneumonia (CAP) and peritonitis sepsis cases, and 477 controls from the United Kingdom. | 0.000814326 | 2015 | MBL2 | 10 | 52771466 | C | T |
| rs4986790 | 21214494 | 7099 | TLR4 | umls:C0031154 | BeFree | TLR4 A896G polymorphism (rs4986790) is a functional polymorphism resulting in hypo-responsiveness of the receptor, thus resulting in peritoneal inflammation. | 0.000542884 | 2011 | TLR4 | 9 | 117713024 | A | G |
| rs5030737 | 25969530 | 4153 | MBL2 | umls:C0031154 | BeFree | We genotyped and analyzed 4 important MBL2 single nucleotide polymorphisms (SNPs; rs5030737, rs1800450, rs1800451, and rs7096206) in 1839 European community-acquired pneumonia (CAP) and peritonitis sepsis cases, and 477 controls from the United Kingdom. | 0.000814326 | 2015 | MBL2 | 10 | 52771482 | G | A |
| rs7096206 | 25969530 | 4153 | MBL2 | umls:C0031154 | BeFree | We genotyped and analyzed 4 important MBL2 single nucleotide polymorphisms (SNPs; rs5030737, rs1800450, rs1800451, and rs7096206) in 1839 European community-acquired pneumonia (CAP) and peritonitis sepsis cases, and 477 controls from the United Kingdom. | 0.000814326 | 2015 | MBL2 | 10 | 52771925 | G | C |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:12) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0031154 | ampicillin | D000667 | 69-53-4 | peritonitis | MESH:D010538 | therapeutic | 3888810 | ||
| C0031154 | cefotaxime | D002439 | 63527-52-6 | peritonitis | MESH:D010538 | therapeutic | 11280580 | ||
| C0031154 | ceftazidime | D002442 | 78439-06-2 | peritonitis | MESH:D010538 | therapeutic | 7827199 | ||
| C0031154 | chloramphenicol | D002701 | 56-75-7 | peritonitis | MESH:D010538 | marker/mechanism | 6071896 | ||
| C0031154 | ciprofloxacin | D002939 | 85721-33-1 | peritonitis | MESH:D010538 | therapeutic | 7566587 | ||
| C0031154 | fluconazole | D015725 | 86386-73-4 | peritonitis | MESH:D010538 | therapeutic | 7566587 | ||
| C0031154 | methotrexate | D008727 | 1959/5/2 | peritonitis | MESH:D010538 | marker/mechanism | 10576662 | ||
| C0031154 | mitoxantrone | D008942 | 65271-80-9 | peritonitis | MESH:D010538 | marker/mechanism | 10370195 | ||
| C0031154 | morphine | D009020 | 57-27-2 | peritonitis | MESH:D010538 | therapeutic | 15770054 | ||
| C0031154 | piperacillin | D010878 | 61477-96-1 | peritonitis | MESH:D010538 | therapeutic | 16369182 | ||
| C0031154 | vancomycin | D014640 | 1404-90-6 | peritonitis | MESH:D010538 | therapeutic | 9560111 | ||
| C0031154 | vinblastine | D014747 | 865-21-4 | peritonitis | MESH:D010538 | marker/mechanism | 4688040 | ||
FDA approved drug and dosage information(Total Drugs:2) | ||||||||
|---|---|---|---|---|---|---|---|---|
| DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
| MESH:D010538 | cipro | ciprofloxacin | 400MG/40ML (10MG/ML) | INJECTABLE;INJECTION | Discontinued | None | Yes | No |
| MESH:D010538 | cipro | ciprofloxacin | 250MG/5ML | FOR SUSPENSION;ORAL | Prescription | AB | Yes | No |
FDA labeling changes(Total Drugs:2) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
| MESH:D010538 | 03/25/2004 | cipro | ciprofloxacin | Complicated UTI and pyelonephritis | Indicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1 17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1 17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectively | Labeling | B | - | - | - | Bayer | 12/18/2003 | FALSE' |
| MESH:D010538 | 03/25/2004 | cipro | ciprofloxacin | Complicated UTI and pyelonephritis | Indicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1 17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1 17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectively | Labeling | B | - | - | - | Bayer | 12/18/2003 | FALSE' |